Search Result

Results for "

striatum

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (15) Adenosine Receptor (1) Adenylate Cyclase (3) Adrenergic Receptor (1) Aminopeptidase (1) Apoptosis (2) Bcl-2 Family (1) Biochemical Assay Reagents (1) Calcium Channel (2) Cholinesterase (ChE) (2) COMT (1) COX (2) DNA Methyltransferase (1) Dopamine Receptor (23) Dopamine Transporter (1) Drug Derivative (2) Drug Isomer (1) Endogenous Metabolite (5) GABA Receptor (2) iGluR (4) Isotope-Labeled Compounds (2) mAChR (1) Monoamine Oxidase (3) nAChR (3) Neurokinin Receptor (2) NF-κB (1) NO Synthase (2) Opioid Receptor (2) PGE synthase (1) Phosphodiesterase (PDE) (3) Prostaglandin Receptor (1) Reactive Oxygen Species (ROS) (4) Reference Standards (6) Sigma Receptor (1) Thyroid Hormone Receptor (1) α-synuclein (1)
By Research Areas:	Cancer (2) Cardiovascular Disease (2) Endocrinology (2) Inflammation/Immunology (4) Metabolic Disease (10) Neurological Disease (63)
Click Chemistry:	Alkynes (1)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N2332A

Methyllycaconitine citrate Maximum Cited Publications 43 Publications Verification MLA citrate	nAChR	Neurological Disease
Methyllycaconitine (MLA) citrate is a potent, selective, CNS-penetrant, competitive α7nAChR antagonist. Methyllycaconitine citrate alleviates amyloid-β peptides-induced cytotoxicity in SH-SY5Y cells. Methyllycaconitine citrate prevents methamphetamine-induced effects in mouse striatum. Methyllycaconitine citrate can be used for neurological disease research, such as Alzheimer’s disease .

HY-B2194

γ-Oryzanol 5+ Cited Publications	DNA Methyltransferase	Metabolic Disease Cancer
γ-Oryzanol is a potent DNA methyltransferases (DNMTs) inhibitor in the striatum of mice. γ-Oryzanol significantly inhibits the activities of DNMT1 (IC₅₀=3.2 μM), DNMT3a (IC₅₀=22.3 μM).

HY-113149A

Argininosuccinic acid disodium	Endogenous Metabolite Reactive Oxygen Species (ROS)	Neurological Disease Metabolic Disease Inflammation/Immunology
Argininosuccinic acid disodium is an intermediate metabolite in the urea cycle, and its level is associated with argininosuccinic aciduria. Argininosuccinic acid disodium can induce oxidative stress, leading to lipid and protein oxidation, reduction of glutathione, and decrease in antioxidant enzyme activity. Argininosuccinic acid disodium can be converted into guanidinosuccinic acid, a nitric oxide mimic, under the action of nitric oxide-derived free radicals. Argininosuccinic acid disodium can be used in the research of metabolic diseases, renal failure, nervous system diseases, etc .

HY-14197A

Clorgyline hydrochloride 5+ Cited Publications	Monoamine Oxidase	Metabolic Disease
Clorgyline hydrochloride is an irreversible and selective inhibitor of monoamine oxidase A (MAO-A) that is used in scientific research, structurally related to Pargyline (HY-A0091A). Clorgyline hydrochloride has little effect on the amounts of conjugated dopamine (DA) present in superfusate of slices from rat striatum. Clorgyline hydrochloride contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups .

HY-B0344

Methscopolamine bromide 1 Publications Verification (-)-Scopolamine methyl bromide; Hyoscine methyl bromide	mAChR	Neurological Disease
Methscopolamine bromide ((-)-Scopolamine methyl bromide; Hyoscine methyl bromide) is a peripherally acting muscarinic receptor (mAChR) antagonist that cannot cross the blood-brain barrier. Methscopolamine bromide blocks the muscarinic negative feedback regulation of acetylcholine release from striatal cholinergic terminals, thereby increasing acetylcholine release in the striatum of freely moving rats. Methscopolamine bromide does not induce motor excitation in freely moving rats, nor does it alter the duration of ethanol-induced loss of righting reflex in mice. Methscopolamine bromide fails to antagonize the arecoline-mediated reduction in the duration of ethanol-induced loss of righting reflex in mice .

HY-107343

Docosahexaenoic acid ethyl ester Ethyl docosahexaenoate	COX	Neurological Disease Metabolic Disease
Docosahexaenoic acid ethyl ester (Ethyl docosahexaenoate) is a 90% concentrated ethyl ester of docosahexaenoic acid manufactured from the microalgal oil. Docosahexaenoic acid ethyl ester enhances 6-hydroxydopamine-induced neuronal damage by induction of lipid peroxidation in mouse striatum. Docosahexaenoic acid (DHA) is a key component of the cell membrane, and its peroxidation is inducible due to the double-bond chemical structure. Docosahexaenoic acid has neuroprotective effects .

HY-113149

Argininosuccinic acid	Endogenous Metabolite Reactive Oxygen Species (ROS)	Neurological Disease Metabolic Disease Inflammation/Immunology
Argininosuccinic acid is an intermediate metabolite in the urea cycle, and its level is associated with argininosuccinic aciduria. Argininosuccinic acid can induce oxidative stress, leading to lipid and protein oxidation, reduction of glutathione, and decrease in antioxidant enzyme activity. Argininosuccinic acid can be converted into guanidinosuccinic acid, a nitric oxide mimic, under the action of nitric oxide-derived free radicals. Argininosuccinic acid can be used in the research of metabolic diseases, renal failure, nervous system diseases, etc .

HY-12363

U-69593 1 Publications Verification	Opioid Receptor	Neurological Disease
U-69593 is a potent and selective κ1-opioid receptor agonist . U-69593 attenuates addictive agent-induced behavioral sensitization in the rat . U-69593 reduces anxiety and enhances spontaneous alternation memory in mice . U-69593 reduces calcium-dependent dialysate levels of dopamine and glutamate in the ventral striatum .

HY-145512

N-(α-Linolenoyl) tyrosine NLT	Dopamine Receptor	Neurological Disease
N-(α-Linolenoyl) tyrosine (NLT) is a dopaminergic agonist capable of crossing the blood-brain barrier. N-(α-Linolenoyl) tyrosine increases the level, turnover rate and release amount of dopamine in the striatum. N-(α-Linolenoyl) tyrosine modulates rotational behavior in a rat model with unilateral striatal injury and alleviates excessive blinking symptoms in models induced by dopamine-depleting agents. N-(α-Linolenoyl) tyrosine can be used for research on Parkinson's disease and idiopathic blepharospasm .

HY-101341

RS 67333 hydrochloride 1 Publications Verification	5-HT Receptor	Neurological Disease
RS 67333 hydrochloride is a potent and selective 5-HT4 receptor (5-HT4R) partial agonist with a pK_i of 8.7 in guinea-pig striatum. RS 67333 hydrochloride exhibits lower affinities at several other receptors including 5-HT1A, 5-HT1D, 5-HT2A, 5-HT2C, dopamine D1, D2 and muscarinic M1-M3 receptors. RS 67333 hydrochloride has neuroprotective effects, and can be used for Alzheimer's disease research .

HY-B1752

Quinpirole 4 Publications Verification LY 171555; (-)-LY 141865	Dopamine Receptor Calcium Channel Bcl-2 Family iGluR Apoptosis	Neurological Disease
Quinpirole (LY 171555; (-)-LY 141865) is a D2/D3 dopamine receptor agonist and a CaV1.3 calcium channel modulator. Quinpirole normalizes dendritic spine density in dopamine-depleted striatum, upregulates the protein expression of BCL2 and GluR2, downregulates the protein expression of BAX, and delays the onset of seizures. Quinpirole enhances learning and memory, inhibits neuronal apoptosis (apoptosis), and induces anxiety-like, stereotyped, and compulsive behaviors. Quinpirole disrupts prepulse inhibition in rhesus monkeys, enhances the activity of paraventricular thalamic neurons to promote recovery from Isoflurane anesthesia, and alters the composition of the gut microbiota in rats. Quinpirole can be used in research related to dyskinesia, pain, epilepsy, and neurological disorders including anxiety disorder, obsessive-compulsive disorder, and schizophrenia .

HY-E70199

Aminopeptidase N (rat) APN/CD13	Aminopeptidase	Cardiovascular Disease
Aminopeptidase N (rat) (APN/CD13) is a Zn ²⁺-dependent membrane-bound exopeptidase that preferentially degrades proteins and peptides with N-terminal neutral amino acids. Aminopeptidase N (rat) is inhibited by angiotensin IV and participates in the regulation of angiotensin IV half-life in the rat striatum .

HY-102050

PF-05085727	Phosphodiesterase (PDE)	Neurological Disease
PF-05085727 is a potent, selective and brain penetrant inhibitor of cGMP-dependent PDE2A (IC₅₀=2 nM). PF-05085727 inhibits PDE2A >4,000-fold selectivity over PDE1 and PDE3-11 .

HY-120511

KNT-127 1 Publications Verification	Opioid Receptor	Neurological Disease
KNT-127 is a selective and BBB-penetrant δ-opioid receptor (DOR) agonist (K_i = 0.16 nM). KNT-127 is highly selective to the δ receptor, with Ki values of 0.16, 21.3 and 153 nM for δ, μ and κ receptors, respectively. KNT-127 acts as a biased ligand that mainly activates cyclic adenosine monophosphate (cAMP) signaling with lower beta-arrestin signaling activation. KNT-127 increases the release of dopamine and L-glutamate in the striatum, nucleus accumbens, and prefrontal cortex. KNT-127 exhibits antidepressant- and anxiolytic-like effects. KNT-127 can be studied in research on neurological diseases .

HY-P1764

Secretoneurin, rat	Dopamine Receptor	Neurological Disease
Secretoneurin, rat, a 33-amino acid polypeptide, is generated by proteolytic processing of secretogranin II (SgII). Secretoneurin, rat induces dopamine release in the rat striatum in vivo and in vitro, and it exerts a very strong chemotactic effect on monocytes and eosinophils but not on granulocytes .

HY-42849A

Sultopride hydrochloride 1 Publications Verification LIN-1418 hydrochloride	Dopamine Receptor	Neurological Disease
Sultopride hydrochloride (LIN-1418 hydrochloride) is a selective antagonist of dopamine D2 receptor.

HY-160959

AN317	nAChR	Neurological Disease
AN317 is a selective agonist for α6β2-containing nicotinic acetylcholine receptor (nAChR) with K_i of 6.2 nM and 4.1 nM, for α6/α3β2β3 receptor and α4β2 receptor, respectively. AN317 induces dopamine release in the synaptosomes of the rat striatum, enhances dopaminergic neuronal activity in substantia nigra, and exhibits protective efficacy to rat neurons against dopamine neurotoxin MPP ⁺. AN317 exhibits good pharmacokinetic characteristics in rats. AN317 penetrates the blood-brain barrier (BB) .

HY-103430A

SKF-83566 2 Publications Verification	Dopamine Receptor 5-HT Receptor Adenylate Cyclase	Neurological Disease
SKF-83566 is a potent, blood-brain permeable and orally active D1-like dopamine receptor (D1DR) antagonist and a weaker competitive antagonist at the vascular 5-HT₂ receptor (K_i=11 nM) . SKF-83566 is a competitive DAT (dopamine transporter) inhibitor with an IC₅₀ of 5.7 μM . SKF-83566 also shows selective inhibition for adenylyl cyclase 2 (AC2) over AC₁ and AC₅ in the isolated rabbit thoracic aorta . SKF-83566 can be used for research of parkinson’s disease and nicotine craving alleviation .

HY-NP180

Progesterone/BSA	Calcium Channel	Metabolic Disease
Progesterone/BSA is a conjugate of Progesterone (HY-N0437) and bovine serum albumin (BSA). Progesterone/BSA cannot penetrate the plasma membrane of human sperm, but still rapidly elevates intracellular free calcium and induces the acrosome reaction. Progesterone/BSA can also act as a probe to specifically bind to progesterone-binding proteins on the membrane of rat brain synaptosomes .

HY-106584

Mosapramine Clospipramine	Drug Derivative Dopamine Receptor 5-HT Receptor	Neurological Disease
Mosapramine (Clospipramine) is an orally active antipsychotic agent and one of the metabolites of Clocapramine (HY-B2073) after oral absorption. Mosapramine exerts its effects by specifically binding to striatal dopamine D2 receptors and frontal lobe 5-HT2 receptors, with a D2/5-HT2 receptor occupancy ratio of 7.4. Mosapramine induces typical neuropharmacological responses in rat brain regions, including extrapyramidal symptoms, hyperprolactinemia, increased salivation, constipation, and upregulated Fos protein expression. Mosapramine also features a reduced incidence of weight loss. Mosapramine is applicable to research related to schizophrenia .

HY-A0151

Thioproperazine 2 Publications Verification RP 7843; SKF 5883; Thioperazine	Dopamine Receptor	Neurological Disease
Thioproperazine (RP 7843) is an orally active antipsychotic agent with calming, antiemetic activity. Thioproperazine is effective in promoting the release of dopamine in rat striatum. Thioproperazine can be used in studies of schizophrenia and bipolar disorder .

HY-124501

LY 165163 p-NH2-PE-TFMPP	5-HT Receptor	Neurological Disease
LY 165163 is a potent 5-HT presynaptic receptor agonist. LY 165163 significantly decreases 5-HTP accumulation and increases DOPA accumulation in the cortex and striatum .

HY-P3800

[Glp5] Substance P (5-11)	Neurokinin Receptor	Neurological Disease Endocrinology
[Glp5] Substance P (5-11) is an octapeptide. [Glp5] Substance P (5-11) is one of the main substance P fragments in rat central nervous system (CNS). [Glp5] Substance P (5-11) locally modulates dopamine release in rat striatum .

HY-14547A

Bifeprunox mesylate	Dopamine Receptor 5-HT Receptor	Neurological Disease
Bifeprunox mesylate is a potent dopamine D2-like and 5-HT1A receptor partial agonist with pK_is of 7.19 and 8.83 for cortex 5-HT1A and striatum D2, and a pEC₅₀ of 6.37 for hippocampus 5-HT1A, respectively. Bifeprunox mesylate is an antipsychotic for the research of schizophrenia .

HY-14547

Bifeprunox	Dopamine Receptor 5-HT Receptor	Neurological Disease
Bifeprunox is a potent dopamine D2-like and 5-HT1A receptor partial agonist with pK_is of 7.19 and 8.83 for cortex 5-HT1A and striatum D2, and a pEC₅₀ of 6.37 for hippocampus 5-HT1A, respectively. Bifeprunox is an antipsychotic for the research of schizophrenia .

HY-42849

Sultopride LIN-1418	Dopamine Receptor	Neurological Disease
Sultopride (LIN-1418) is a selective antagonist of dopamine D2 receptor.

HY-107343R

Docosahexaenoic acid ethyl ester (Standard) Ethyl docosahexaenoate (Standard)	Endogenous Metabolite Reference Standards	Neurological Disease Metabolic Disease
Docosahexaenoic acid ethyl ester (Standard) is the analytical standard of Docosahexaenoic acid ethyl ester. This product is intended for research and analytical applications. Docosahexaenoic acid ethyl ester (Ethyl docosahexaenoate) is a 90% concentrated ethyl ester of docosahexaenoic acid manufactured from the microalgal oil. Docosahexaenoic acid ethyl ester enhances 6-hydroxydopamine-induced neuronal damage by induction of lipid peroxidation in mouse striatum. Docosahexaenoic acid (DHA) is a key component of the cell membrane, and its peroxidation is inducible due to the double-bond chemical structure. Docosahexaenoic acid has neuroprotective effects .

HY-B0884

Minaprine	Monoamine Oxidase Cholinesterase (ChE)	Neurological Disease
Minaprine is a brain-penetrant monoamine oxidase inhibitor. Minaprine also weakly inhibits acetylcholinesterase (AChE) activity. Minaprine reduces intraneuronal dopamine metabolism, lowers striatal homovanillic acid and dihydroxyphenylacetic acid levels, and raises striatal 3-methoxytyramine and 5-hydroxytryptamine levels. Minaprine exhibits convulsant, antidepressant properties .

HY-12520

SKF 38393	Dopamine Receptor	Neurological Disease Cancer
SKF 38393 is a selective dopamine D1 receptor agonist. SKF 38393 activates the cAMP signaling pathway and promotes dopamine release in the developing rat striatum. SKF 38393 inhibits MCF-7 breast cancer cell proliferation (IC₅₀=0.1 μM). SKF 38393 is promising for research of neurodevelopmental disorders, dopamine-related diseases (e.g., Parkinson’s, dopamine deficiency), and cancers .

HY-113726

Nerisopam GYKI52322; EGIS-6775	GABA Receptor	Neurological Disease
Nerisopam is an orally active gamma-aminobutyric acid (GABA) receptor agonist. Nerisopam is an anxiolytic and antipsychotic homophthalazine. Nerisopam induces rapid, intense expression of Fos-like immunoreactivity in the rostral, dorsomedial and lateral parts of the striatum in the rat .

HY-114578

PD 118717	Dopamine Receptor 5-HT Receptor	Neurological Disease
PD 118717 is a selective dopamine (DA) D-2 autoreceptor agonist. PD 118717 has significant affinity for 5-HT1A but not 5-HT1B and 5-HT2 receptors. PD 118717 is active in antagonizing the tau-Butyrolactone-induced accumulation of dopa in rat striatum and mesolimbic regions. PD 118717 exhibits an antipsychotic-like profile .

HY-14197AR

Clorgyline hydrochloride (Standard)	Monoamine Oxidase Reference Standards	Metabolic Disease
Clorgyline hydrochloride (Standard) is the analytical standard of Clorgyline hydrochloride. This product is intended for research and analytical applications. Clorgyline hydrochloride is an irreversible and selective inhibitor of monoamine oxidase A (MAO-A) that is used in scientific research, structurally related to Pargyline (HY-A0091A). Clorgyline hydrochloride has little effect on the amounts of conjugated dopamine (DA) present in superfusate of slices from rat striatum. Clorgyline hydrochloride contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups .

HY-136800

Posatirelin	Thyroid Hormone Receptor	Endocrinology
Posatirelin, a TRH analog, increases monoamine metabolites in the cerebral cortex, nucleus accumbens, and striatum, and possibly exerts CNS activating effects through a modification of several neurotransmitter systems .

HY-19061

CGP 28014	COMT	Neurological Disease
CGP 28014 is a catechol-O-methyltransferase inhibitor. CGP 28014 can lower HVA levels and increase DOPAC levels in the striatum of rats, making it useful for research on Parkinson's disease .

HY-19845A

Ordopidine hydrochloride ACR-325 hydrochloride	Dopamine Receptor	Neurological Disease
Ordopidine hydrochloride is a modulator of dopamine receptor extracted from patent WO/2005/121087A1, compound example 2; exhibits an ED₅₀ of 68 μmol/kg on increase of DOPAC in the rat striatum.

HY-117162

S 1432	Cholinesterase (ChE)	Neurological Disease
S 1432 is a central nervous system depressant with anticonvulsant and muscle relaxant effects. S 1432 significantly reduces acetylcholine levels in the striatum inhibits convulsions induced by pentylenetetrazol. S 1432 can be used in the development of psychotropic drugs .

HY-101342

RS 67506 hydrochloride	5-HT Receptor	Neurological Disease
RS 67506 hydrochloride is a 5-HT4 receptor agonist. The pKi value of RS 67506 hydrochloride for 5-HT4 in guinea pig striatum is 8.8. RS 67506 hydrochloride can be used in neuro-related research .

HY-106437

ELB-139	GABA Receptor	Neurological Disease
ELB-139 is a progesterone analogue. ELB-139 is a GABAA receptor partial agonist. ELB-139 has anxiolytic and anticonvulsant activity. ELB-139 induces increase of extracellular 5-HT in the striatum and the medial prefrontal cortex of rats .

HY-119385

Savoxepin mesylate	Dopamine Receptor	Neurological Disease
Savoxepin mesylate is a D2 dopamine receptor (D2 Dopamine Receptor) antagonist with antipsychotic activity. Savoxepin mesylate selectively blocks dopamine D2 receptors in the hippocampus while having no significant effect on D2 receptors in the striatum. This selective blockade helps reduce the risk of extrapyramidal side effects (EPS) .

HY-106153B

E-5842 citrate	Sigma Receptor	Neurological Disease
E-5842 citrate is a σ receptor ligand (K_i: 4 nM for σ1 receptor). E-5842 citrate increases levels of Fos in the medial prefrontal cortex and the nucleus accumbens, without affecting the levels of the protein in the striatum. E-5842 citrate can be used in the research of psychiatric disorders .

HY-110024A

S-14506	5-HT Receptor	Neurological Disease
S-14506 hydrochloride is a potent 5-HT1A agonist. S-14506 hydrochloride displays dopamine antagonist properties by blocking dopamine D2 receptors. S-14506 hydrochloride inhibits the in vivo binding of [3H]raclopride in striatum and olfactory bulbs. S-14506 hydrochloride has the potential for the research of anxiolytic agent .

HY-P2307

Tat-NR2Baa	iGluR NO Synthase	Neurological Disease
Tat-NR2BAA is the control peptide of Tat-NR2B9c (HY-P0117), inactive. The sequence of Tat-NR2BAA is similar to Tat-NR2B9c, but it has a double-point mutation in the COOH terminal tSXV motif, making it incapable of binding PSD-95. Tat-NR2B9c is a membrane-permeant peptide and disrupts PSD-95/NMDAR binding, correlate with uncoupling NR2B- and/or NR2A-type NMDARs from PSD-95 .

HY-42849AR

Sultopride hydrochloride (Standard) LIN-1418 hydrochloride (Standard)	Dopamine Receptor Reference Standards	Neurological Disease
Sultopride hydrochloride (Standard) is the analytical standard of Sultopride hydrochloride. This product is intended for research and analytical applications. Sultopride hydrochloride (LIN-1418 hydrochloride) is a selective antagonist of dopamine D2 receptor.

HY-P2307A

Tat-NR2Baa TFA	iGluR NO Synthase	Neurological Disease
Tat-NR2BAA TFA is the control peptide of Tat-NR2B9c (HY-P0117), inactive. The sequence of Tat-NR2BAA TFA is similar to Tat-NR2B9c, but it has a double-point mutation in the COOH terminal tSXV motif, making it incapable of binding PSD-95. Tat-NR2B9c is a membrane-permeant peptide and disrupts PSD-95/NMDAR binding, correlate with uncoupling NR2B- and/or NR2A-type NMDARs from PSD-95 .

HY-119409

Levophacetoperane Phacetoperane free base	Dopamine Transporter	Neurological Disease
Levophacetoperane (Phacetoperane free base) competitively inhibits the uptake of norepinephrin and dopamine .

HY-153127

Florbenazine AV-133	Biochemical Assay Reagents	Neurological Disease
Florbenazine (AV-133) is a diagnostic imaging agent targeting the central nervous system monoamine transporter VMAT2, and its F-18 labeled form can be used for PET scanning. The biodistribution of [18F]Florbenazine in mice shows a high striatum/cerebellum ratio (0.48), which can be used for the diagnostic research of neurodegenerative diseases (including dementia with Lewy bodies and Parkinson's disease) .

HY-110024

S-14506 hydrochloride	5-HT Receptor Dopamine Receptor	Neurological Disease
S-14506 hydrochloride is a potent 5-HT1A agonist, as well as 5-HT_2A/2C antagonist. S-14506 hydrochloride displays dopamine antagonist properties by blocking dopamine D2 receptors. S-14506 hydrochloride inhibits the in vivo binding of [3H]raclopride in striatum and olfactory bulbs. S-14506 hydrochloride has the potential for the research of anxiolytic agent .

HY-107343S

Docosahexaenoic acid ethyl ester-d5 Ethyl docosahexaenoate-d₅	Isotope-Labeled Compounds	Neurological Disease Metabolic Disease
Docosahexaenoic acid ethyl ester-d₅ is the deuterium labeled Docosahexaenoic acid ethyl ester. Docosahexaenoic acid ethyl ester (Ethyl docosahexaenoate) is a 90% concentrated ethyl ester of docosahexaenoic acid manufactured from the microalgal oil. Docosahexaenoic acid ethyl ester enhances 6-hydroxydopamine-induced neuronal damage by induction of lipid peroxidation in mouse striatum. Docosahexaenoic acid (DHA) is a key component of the cell membrane, and its peroxidation is inducible due to the double-bond chemical structure. Docosahexaenoic acid has neuroprotective effects .

HY-107343S1

Docosahexaenoic acid ethyl ester-d5-1 Ethyl docosahexaenoate-d₅-1	Isotope-Labeled Compounds	Others
Docosahexaenoic acid ethyl ester-d₅-1 is the deuterium labeled Docosahexaenoic acid ethyl ester. Docosahexaenoic acid ethyl ester (Ethyl docosahexaenoate) is a 90% concentrated ethyl ester of docosahexaenoic acid manufactured from the microalgal oil. Docosahexaenoic acid ethyl ester enhances 6-hydroxydopamine-induced neuronal damage by induction of lipid peroxidation in mouse striatum. Docosahexaenoic acid (DHA) is a key component of the cell membrane, and its peroxidation is inducible due to the double-bond chemical structure. Docosahexaenoic acid has neuroprotective effects .

HY-19845

Ordopidine ACR-325	Dopamine Receptor	Neurological Disease
Ordopidine is a dopamine D2 receptor antagonist. Ordopidine can inhibit hyperactivity caused by psychostimulants. Ordopidine can be used in neurological research .

Cat. No.	Product Name	Target	Research Area

HY-145512

N-(α-Linolenoyl) tyrosine NLT	Dopamine Receptor	Neurological Disease
N-(α-Linolenoyl) tyrosine (NLT) is a dopaminergic agonist capable of crossing the blood-brain barrier. N-(α-Linolenoyl) tyrosine increases the level, turnover rate and release amount of dopamine in the striatum. N-(α-Linolenoyl) tyrosine modulates rotational behavior in a rat model with unilateral striatal injury and alleviates excessive blinking symptoms in models induced by dopamine-depleting agents. N-(α-Linolenoyl) tyrosine can be used for research on Parkinson's disease and idiopathic blepharospasm .

HY-P1764

Secretoneurin, rat	Dopamine Receptor	Neurological Disease
Secretoneurin, rat, a 33-amino acid polypeptide, is generated by proteolytic processing of secretogranin II (SgII). Secretoneurin, rat induces dopamine release in the rat striatum in vivo and in vitro, and it exerts a very strong chemotactic effect on monocytes and eosinophils but not on granulocytes .

HY-P3800

[Glp5] Substance P (5-11)	Neurokinin Receptor	Neurological Disease Endocrinology
[Glp5] Substance P (5-11) is an octapeptide. [Glp5] Substance P (5-11) is one of the main substance P fragments in rat central nervous system (CNS). [Glp5] Substance P (5-11) locally modulates dopamine release in rat striatum .

HY-P2307

Tat-NR2Baa	iGluR NO Synthase	Neurological Disease
Tat-NR2BAA is the control peptide of Tat-NR2B9c (HY-P0117), inactive. The sequence of Tat-NR2BAA is similar to Tat-NR2B9c, but it has a double-point mutation in the COOH terminal tSXV motif, making it incapable of binding PSD-95. Tat-NR2B9c is a membrane-permeant peptide and disrupts PSD-95/NMDAR binding, correlate with uncoupling NR2B- and/or NR2A-type NMDARs from PSD-95 .

HY-P2307A

Tat-NR2Baa TFA	iGluR NO Synthase	Neurological Disease
Tat-NR2BAA TFA is the control peptide of Tat-NR2B9c (HY-P0117), inactive. The sequence of Tat-NR2BAA TFA is similar to Tat-NR2B9c, but it has a double-point mutation in the COOH terminal tSXV motif, making it incapable of binding PSD-95. Tat-NR2B9c is a membrane-permeant peptide and disrupts PSD-95/NMDAR binding, correlate with uncoupling NR2B- and/or NR2A-type NMDARs from PSD-95 .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-B2194

γ-Oryzanol 5+ Cited Publications	Monophenols other families Classification of Application Fields Phenols Plants Disease Research Fields Steroids Source Classification Cancer	DNA Methyltransferase
γ-Oryzanol is a potent DNA methyltransferases (DNMTs) inhibitor in the striatum of mice. γ-Oryzanol significantly inhibits the activities of DNMT1 (IC₅₀=3.2 μM), DNMT3a (IC₅₀=22.3 μM).

HY-113149A

Argininosuccinic acid disodium	Classification of Application Fields Ketones, Aldehydes, Acids Endogenous metabolite Inflammation/Immunology Disease Research Fields Source Classification	Endogenous Metabolite Reactive Oxygen Species (ROS)
Argininosuccinic acid disodium is an intermediate metabolite in the urea cycle, and its level is associated with argininosuccinic aciduria. Argininosuccinic acid disodium can induce oxidative stress, leading to lipid and protein oxidation, reduction of glutathione, and decrease in antioxidant enzyme activity. Argininosuccinic acid disodium can be converted into guanidinosuccinic acid, a nitric oxide mimic, under the action of nitric oxide-derived free radicals. Argininosuccinic acid disodium can be used in the research of metabolic diseases, renal failure, nervous system diseases, etc .

HY-113149

Argininosuccinic acid	Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Endogenous metabolite Inflammation/Immunology Disease Research Fields Source Classification	Endogenous Metabolite Reactive Oxygen Species (ROS)
Argininosuccinic acid is an intermediate metabolite in the urea cycle, and its level is associated with argininosuccinic aciduria. Argininosuccinic acid can induce oxidative stress, leading to lipid and protein oxidation, reduction of glutathione, and decrease in antioxidant enzyme activity. Argininosuccinic acid can be converted into guanidinosuccinic acid, a nitric oxide mimic, under the action of nitric oxide-derived free radicals. Argininosuccinic acid can be used in the research of metabolic diseases, renal failure, nervous system diseases, etc .

HY-N2332

Methyllycaconitine MLA	Structural Classification Alkaloids Piperidine Alkaloids Ranunculaceae Delphinium ajacis Plants Source Classification	nAChR
Methyllycaconitine (MLA) is a potent, selective, CNS-penetrant, competitive α7nAChR antagonist. Methyllycaconitine alleviates amyloid-β peptides-induced cytotoxicity in SH-SY5Y cells. Methyllycaconitine prevents methamphetamine-induced effects in mouse striatum. Methyllycaconitine can be used for neurological disease research, such as Alzheimer’s disease .

Cat. No.	Product Name	Chemical Structure

HY-107343S

Docosahexaenoic acid ethyl ester-d5

Docosahexaenoic acid ethyl ester-d₅ is the deuterium labeled Docosahexaenoic acid ethyl ester. Docosahexaenoic acid ethyl ester (Ethyl docosahexaenoate) is a 90% concentrated ethyl ester of docosahexaenoic acid manufactured from the microalgal oil. Docosahexaenoic acid ethyl ester enhances 6-hydroxydopamine-induced neuronal damage by induction of lipid peroxidation in mouse striatum. Docosahexaenoic acid (DHA) is a key component of the cell membrane, and its peroxidation is inducible due to the double-bond chemical structure. Docosahexaenoic acid has neuroprotective effects .

HY-107343S1

Docosahexaenoic acid ethyl ester-d5-1

Docosahexaenoic acid ethyl ester-d₅-1 is the deuterium labeled Docosahexaenoic acid ethyl ester. Docosahexaenoic acid ethyl ester (Ethyl docosahexaenoate) is a 90% concentrated ethyl ester of docosahexaenoic acid manufactured from the microalgal oil. Docosahexaenoic acid ethyl ester enhances 6-hydroxydopamine-induced neuronal damage by induction of lipid peroxidation in mouse striatum. Docosahexaenoic acid (DHA) is a key component of the cell membrane, and its peroxidation is inducible due to the double-bond chemical structure. Docosahexaenoic acid has neuroprotective effects .

Cat. No.	Product Name		Classification

HY-14197A

Clorgyline hydrochloride 5+ Cited Publications		Alkynes
Clorgyline hydrochloride is an irreversible and selective inhibitor of monoamine oxidase A (MAO-A) that is used in scientific research, structurally related to Pargyline (HY-A0091A). Clorgyline hydrochloride has little effect on the amounts of conjugated dopamine (DA) present in superfusate of slices from rat striatum. Clorgyline hydrochloride contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

striatum

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

NaturalProducts

Isotope-Labeled Compounds

Click Chemistry

Natural
Products